HIV/hepatitis C virus (HCV) co-infection leads to major complications, and noninvasive markers developed to stage liver fibrosis could be used as prognostic markers. We aimed to compare the performances of liver stiffness (LS), fibrosis-4 (FIB-4), and aspartate aminotransferase to platelet ratio index (APRI) to predict liver-related events in HIV/HCV co-infected patients.
HIV/HCV co-infected patients from the ANRS CO13 HEPAVIH cohort were included if they had LS, FIB-4, and APRI measurements done in a window of 3 months. Primary outcome was the time between inclusion and occurrence of a liver-related event. Univariable and multivariable Fine and Gray models were performed. Predictive performances were compared by the area under the receiver operating characteristic (AUROC) differences after correction of optimistic by bootstrap samples. Best cutoffs to predict liver-related events were estimated by sensitivity and specificity maximization.
A total of 998 patients were included. Overall, 70.7% were men. Their median age was 46.8 years. According to LS value, 204 (20.4%) patients had cirrhosis. Overall, 39 patients experienced at least one liver-related event. In univariable analysis, LS AUROC curve was significantly superior to FIB-4 and APRI AUROC curves, being 87.9, 78.2, and 75.0%, respectively. After adjustment on age, CD4 levels, and insulin resistance, no differences were observed. The best cutoffs to identify patients at low or high risk of liver-related events were below 8.5, 1.00, and 0.35 and above 16.5, 4.00, and 1.75 for LS, FIB-4, and APRI, respectively.
To predict HCV-related events, APRI had lower performance than LS and FIB-4. FIB-4 is as good as LS to predict HCV-related events, suggesting that it can be used for the management of HIV/HCV co-infected patients and replace LS.
aBordeaux Population Health Research Center, ISPED, Inserm, Team MORPH3EUS, UMR 1219, Bordeaux University
bInfectious and Tropical Disease Unit, Bordeaux, University Hospital Center, Pellegrin Hospital
dInternal Medicine Unit, Saint-André Hospital, Bordeaux University Hospital Center
eMedical Information Unit, Public Health Pole, Bordeaux University Hospital Center, Bordeaux
fLiver Unit, Paris Public Hospitals, Cochin Hospital, INSERM U-1223, PasteurInstitute, Paris-Descartes University
gInfectious and Tropical Disease Unit, Paris Public Hospitals, Saint-Antoine Hospital
hUMR S1136, Pierre Louis Epidemiology andPublic Health Institute, Pierre and Marie Curie University
iInfectious and Tropical Disease Unit, Paris Public Hospitals de Paris, Tenon Hospital
jInfectious and Tropical Disease Unit, Paris Public Hospitals, Bicêtre Hospital, University Hospitals Paris Sud
kParis Sud University
lDepartment of Internal Medicine and Clinical Immunology, Paris Public Hospitals, Pitié-Salpétrière Hospital
mInfectious and Tropical Disease Unit, Paris Publics Hospitals, Saint-Louis Hospitals
nInfectious and Tropical Disease Unit, AP-HP, Bichat Claude Bernard Hospital
oInfectious and Tropical Disease Unit, Paris Publics Hospitals, Cochin Hospital
pParis Descartes University, Paris
qInfectious and Tropical Disease Unit, University Hospital Center Lyon, de la Croix Rousse Hospital, Lyon
rINSERM, U912 (SE4S), IRD, UMR-S912- ORS PACA, Regional Health Observatory Provence Alpes Côte d’Azur
sAPHM Sainte-Marguerite, Clinical Immunohematology Unit, Aix Marseille University, Marseille
tInfectious and Tropical Disease Unit, Perpignan Hospital Center, Perpignan
uPurpan Hospital, Internal Medicine, Toulouse University Hospital Center
vToulouse III University
wMedicine Unit, Joseph Ducuing Hospital
xGastroenterology and Hepatology Unit, Purpan Hospital, Toulouse University Hospital Center, Toulouse
yDepartment of Infectiology, Dijon University Hospital Center
zBourgogne University, Dijon
*Infectious and Tropical Disease Unit, Paris Publics Hospitals, Avicenne Hospital
†Paris 13 Nord University,Bobigny
‡Nice University Hospital Center, Infectiology Center, Archet 1 Hospital
§Nice-Sophia Antipolis University, Nice, France
Received 5 October 2018 Accepted 14 January 2019
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website, www.eurojgh.com.
Correspondence to Linda Wittkop, MD, PhD, Bordeaux University/School of Public Health (ISPED), Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, 146 Léo-Saignat Street, 33076 Bordeaux Cedex, France, Tel: + 33 557 574 526; fax: + 33 556 240 081; e-mail: firstname.lastname@example.org